SAN DIEGO, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report third quarter 2016 financial results on Thursday, November 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
| Date: | | | | Thursday, November 3, 2016 |
| Time: | | | | 4:30 p.m. ET |
| Dial-in numbers: | | | | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) |
| Confirmation code: | | | | 1738305 |
| Live webcast: | | | | www.retrophin.com in the "Events & Presentations" section of the "Investors" page |
| | | | | |
A replay of the call will be available from 7:30 p.m. ET, November 3, 2016 to 11:59 p.m. ET, November 10, 2016. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International),
confirmation code 1738305.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by
revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®.
Retrophin.com
Contact:
(Investors)
Chris Cline, CFA
Senior Director, Investor Relations
646-564-3680
IR@retrophin.com
Source:
Retrophin, Inc.
News Provided by Acquire Media